Free Trial

DaVita (DVA) Stock Price, News & Analysis

DaVita logo
$129.55 +1.86 (+1.46%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$129.54 -0.01 (-0.01%)
As of 08/8/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About DaVita Stock (NYSE:DVA)

Key Stats

Today's Range
$127.32
$130.51
50-Day Range
$127.61
$151.47
52-Week Range
$126.07
$179.60
Volume
949,567 shs
Average Volume
883,366 shs
Market Capitalization
$9.26 billion
P/E Ratio
12.74
Dividend Yield
N/A
Price Target
$164.00
Consensus Rating
Hold

Company Overview

DaVita Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

DVA MarketRank™: 

DaVita scored higher than 96% of companies evaluated by MarketBeat, and ranked 45th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DaVita has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    DaVita has only been the subject of 2 research reports in the past 90 days.

  • Read more about DaVita's stock forecast and price target.
  • Earnings Growth

    Earnings for DaVita are expected to grow by 18.12% in the coming year, from $10.76 to $12.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DaVita is 12.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DaVita is 12.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.76.

  • Price to Earnings Growth Ratio

    DaVita has a PEG Ratio of 0.88. PEG Ratios below 1 indicate that a company could be undervalued.

  • Percentage of Shares Shorted

    8.17% of the float of DaVita has been sold short.
  • Short Interest Ratio / Days to Cover

    DaVita has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in DaVita has recently decreased by 3.61%, indicating that investor sentiment is improving.
  • Dividend Yield

    DaVita does not currently pay a dividend.

  • Dividend Growth

    DaVita does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.17% of the float of DaVita has been sold short.
  • Short Interest Ratio / Days to Cover

    DaVita has a short interest ratio ("days to cover") of 7.3.
  • Change versus previous month

    Short interest in DaVita has recently decreased by 3.61%, indicating that investor sentiment is improving.
  • News Sentiment

    DaVita has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 34 news articles for DaVita this week, compared to 12 articles on an average week.
  • Search Interest

    Only 4 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DaVita insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $352,650.00 in company stock.

  • Percentage Held by Insiders

    Only 2.00% of the stock of DaVita is held by insiders.

  • Percentage Held by Institutions

    90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DaVita's insider trading history.
Receive DVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter.

DVA Stock News Headlines

Barclays Sticks to Its Hold Rating for DaVita (DVA)
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
TD Cowen Remains a Hold on DaVita (DVA)
DaVita Healthcare’s Resilient Earnings Call Amid Challenges
DaVita Healthcare’s Resilient Earnings Call Amid Challenges
See More Headlines

DVA Stock Analysis - Frequently Asked Questions

DaVita's stock was trading at $149.55 at the beginning of the year. Since then, DVA shares have decreased by 13.4% and is now trading at $129.5520.

DaVita Inc. (NYSE:DVA) issued its quarterly earnings data on Tuesday, August, 5th. The company reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. The business's revenue for the quarter was up 6.1% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of DaVita: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and others.

Top institutional investors of DaVita include Geode Capital Management LLC (1.55%), KBC Group NV (0.52%), Bank of New York Mellon Corp (0.47%) and Allianz Asset Management GmbH (0.46%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty, Charles Berg, John M Nehra, Phyllis R Yale and Barbara J Desoer.
View institutional ownership trends
.

Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/05/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - OUTP/HM CRE
Sub-Industry
Health Care Services
Current Symbol
NYSE:DVA
CIK
927066
Employees
76,000
Year Founded
1999

Price Target and Rating

High Price Target
$184.00
Low Price Target
$148.00
Potential Upside/Downside
+26.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$10.17
Trailing P/E Ratio
12.74
Forward P/E Ratio
12.04
P/E Growth
0.88
Net Income
$936.34 million
Net Margins
6.35%
Pretax Margin
10.96%
Return on Equity
369.39%
Return on Assets
4.62%

Debt

Debt-to-Equity Ratio
23.18
Current Ratio
1.39
Quick Ratio
1.20

Sales & Book Value

Annual Sales
$12.82 billion
Price / Sales
0.72
Cash Flow
$19.42 per share
Price / Cash Flow
6.67
Book Value
($1.51) per share
Price / Book
-85.80

Miscellaneous

Outstanding Shares
71,500,000
Free Float
70,070,000
Market Cap
$9.26 billion
Optionable
Optionable
Beta
1.09

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSE:DVA) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners